AU5928599A - Methods for treating cell proliferative disorders including cancer - Google Patents

Methods for treating cell proliferative disorders including cancer

Info

Publication number
AU5928599A
AU5928599A AU59285/99A AU5928599A AU5928599A AU 5928599 A AU5928599 A AU 5928599A AU 59285/99 A AU59285/99 A AU 59285/99A AU 5928599 A AU5928599 A AU 5928599A AU 5928599 A AU5928599 A AU 5928599A
Authority
AU
Australia
Prior art keywords
methods
cell proliferative
proliferative disorders
disorders including
including cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59285/99A
Inventor
Undurti Narasimha Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EFA Sciences LLC
Original Assignee
EFA Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EFA Sciences LLC filed Critical EFA Sciences LLC
Publication of AU5928599A publication Critical patent/AU5928599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU59285/99A 1999-09-09 1999-09-20 Methods for treating cell proliferative disorders including cancer Abandoned AU5928599A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39295399A 1999-09-09 1999-09-09
US09392953 1999-09-09
PCT/US1999/021711 WO2001017524A1 (en) 1999-09-09 1999-09-20 Methods for treating cell proliferative disorders including cancer

Publications (1)

Publication Number Publication Date
AU5928599A true AU5928599A (en) 2001-04-10

Family

ID=23552691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59285/99A Abandoned AU5928599A (en) 1999-09-09 1999-09-20 Methods for treating cell proliferative disorders including cancer

Country Status (4)

Country Link
EP (1) EP1214067A1 (en)
JP (1) JP2003508487A (en)
AU (1) AU5928599A (en)
WO (1) WO2001017524A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon Therapeutic intervention to mimic the effect of caloric restriction
CN1555253A (en) * 2001-09-13 2004-12-15 ������ѧ�����о�Ժ Oily composition of taxol,preparation for chemical therapeutic embolism and their producing method
WO2005072306A2 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
WO2006054316A1 (en) * 2004-11-16 2006-05-26 Magene Life Sciences Private Limited Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors
ES2264886B1 (en) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF TUMOR DISEASES.
WO2010079362A1 (en) 2009-01-09 2010-07-15 Hamlet Pharma Ab Complex and production process
PL2643010T3 (en) 2010-11-24 2017-05-31 Hamlet Pharma Ab Biologically active complex and its preparation
JP6211380B2 (en) * 2012-10-17 2017-10-11 丸善製薬株式会社 Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent
WO2014145817A2 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Novel therapeutic target for the treatment of cancers and related therapies and methods
JP7208650B2 (en) * 2017-05-16 2023-01-19 アビリティ ファーマシューティカルズ エス．エル． Drug Combinations for Cancer Treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (en) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd Anticancer agent composition
GB2222080A (en) * 1988-08-15 1990-02-28 Efamol Holdings Nutritional compositions comprising polyunsaturated fatty acid salts
WO1993005774A1 (en) * 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
EP0585057A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Lithium salts of fatty acids for the treatment of viral infections and cancer
JPH0892129A (en) * 1993-10-08 1996-04-09 Kanagawa Kagaku Kenkyusho:Kk Therapeutic agent for ophthalmicus attack
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment

Also Published As

Publication number Publication date
WO2001017524A1 (en) 2001-03-15
EP1214067A1 (en) 2002-06-19
JP2003508487A (en) 2003-03-04

Similar Documents

Publication Publication Date Title
AU2001227966A1 (en) Methods for treating tumors
AU7085100A (en) Method for treating otic disorders
AU3263901A (en) Methods for treating pervasive development disorders
AU7380500A (en) Methods for treating tumors using neutron therapy
AU5057100A (en) Device for carrying out proton therapy
AU2001238126A1 (en) Apparatus for local radiation therapy
AU6528800A (en) Methods and apparatuses for radiation treatment
AU4564200A (en) Method for treating cancer using camptothecin derivatives and 5-fluorouracil
EP1146912A4 (en) Method for improved radiation therapy
AU2879300A (en) Methods for anti-tumor therapy
EP1176964B8 (en) Uses of et743 for treating cancer
AU2001249980A1 (en) Apparatus for local radiation therapy
AU5928599A (en) Methods for treating cell proliferative disorders including cancer
AU2042301A (en) 1-aminoalkyl-1H-indoles for treating glaucoma
AU5042000A (en) Methods of treating proliferative disorders
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
IL147749A0 (en) Methods for treating therapy-resistant tumors
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU2002308642A1 (en) Methods for treating cancer
AU7363000A (en) Method for reducing the risk of cancer
AU7856100A (en) Methods for treating solid tumors with irradiation and bacteria
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU2001236783A1 (en) Apparatus for local radiation therapy
AU1917101A (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase